Liquidity is severely constrained, with cash reserves dwindling to $3.4 million in 2026Q1 while the company continues to burn cash to fund ongoing operations.
| Cash from Operations | -3.71M | 3.82M | 19.35M | -20.71M | -21.26M | -28.66M | -31.46M |
| Operating CF Margin % | - | 12.61% | 34.19% | -44.3% | -55.89% | -91.53% | -133.54% |
| Operating CF Growth % | -657.95% | -80.28% | 193.44% | 2.59% | 25.84% | 8.89% | - |
| Net Income | -419.68M | -358.73M | -72.81M | -114.33M | -23.36M | -88.42M | -47.52M |
| Depreciation & Amortization | 6.49M | 4.62M | 4.05M | 4.15M | 3.96M | 3.78M | 3.78M |
| Stock-Based Compensation | 10.16M | 15.49M | 15.69M | 14.6M | 5.28M | 5.82M | 5.39M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 12.76M | -800K |
| Other Non-Cash Items | 346.87M | 228.47M | 7.58M | 9.08M | -52.8M | 23.79M | 623K |
| Working Capital Changes | 13.4M | 113.97M | 64.84M | 65.8M | 45.67M | 13.6M | 7.06M |
| Change in Receivables | 2.42M | 13.84M | -6.27M | -13.36M | -6.97M | -1.14M | -598K |
| Change in Inventory | 2.63M | 1.8M | 1.46M | -2.84M | 1.18M | -1.42M | 2.38M |
| Change in Payables | 23.68M | 13.12M | 7.42M | 19.88M | 2.81M | -3.84M | -4.06M |
| Cash from Investing | -4.63M | 4.08M | -2.67M | -330K | -2.07M | 0 | -25K |
| Capital Expenditures | -16.24M | -133K | -600K | -30K | -2.07M | 0 | -25K |
| CapEx % of Revenue | 47.97% | 0.44% | 1.06% | 0.06% | 5.43% | - | 0.11% |
| Acquisitions | -7.54M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -20.5M | 4.22M | 0 | -300K | 0 | 0 | 0 |
| Cash from Financing | 7.2M | -5.46M | -18.13M | 23.58M | 21.17M | 28.16M | -19.17M |
| Debt Issued (Net) | 12.32M | -2.81M | -64.21M | 728K | -31.25M | -19.69M | -37.62M |
| Equity Issued (Net) | 15.91M | 27.88M | 44.64M | 25.46M | 96K | 0 | -93.21K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -10M | 0 | 0 | 0 |
| Other Financing | -21.03M | -30.53M | 1.44M | -2.6M | 52.33M | 47.85M | 18.54M |
| Net Change in Cash | -2.45M | 1.68M | -1.46M | 2.54M | -2.15M | -501K | -50.66M |
| Free Cash Flow | -6.59M | 3.68M | 18.75M | -21.04M | -23.32M | -28.66M | -31.49M |
| FCF Margin % | -19.46% | 12.17% | 33.13% | -45.01% | -61.33% | -91.53% | -133.64% |
| FCF Growth % | -142.89% | -80.36% | 189.12% | 9.81% | 18.63% | 8.96% | - |
| FCF per Share | -0.96 | 0.33 | 2.70 | -5.65 | -6.08 | -7.55 | -7.81 |
| FCF Conversion (FCF/Net Income) | 0.02x | -0.01x | -0.27x | 0.18x | 0.91x | 0.32x | 0.66x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and solvency
As reported in recent financial statements, the persistent disconnect between net losses and operating cash flow, exemplified by the 2025Q3 period where net income was -$257.2 million against positive operating cash flow, suggests that accruals and non-cash adjustments are heavily distorting the company's true economic performance.
The reliance on working capital fluctuations to mask underlying operational cash deficits warrants significant caution from investors. This pattern indicates that the company's reported cash flow is not derived from core product profitability but rather from balance sheet management that may not be sustainable.
Based on the provided quarterly data, Scilex has struggled to maintain positive free cash flow, with the most recent 2026Q1 period showing a burn of $4.2 million, underscoring the company's inability to fund its ongoing clinical and operational requirements through internal revenue generation alone.
The erratic nature of FCF margins, which swung from 117% in 2025Q1 to -48.3% in 2026Q1, highlights a lack of operational predictability. This volatility suggests that the business model is currently incapable of self-funding, leaving it perpetually dependent on external capital injections.
According to historical cash flow filings, the company has frequently utilized working capital adjustments, such as the $25.9 million inflow in 2026Q1, to offset operational losses, a trend that suggests the firm is aggressively managing payables or receivables to preserve its dwindling cash reserves.
Investors should monitor whether these working capital swings represent genuine efficiency gains or merely the deferral of obligations. The reliance on these non-operational cash sources appears to be a stop-gap measure that fails to address the fundamental lack of profitability in the core business.
As disclosed in the cash flow statements, Scilex consistently records significant stock-based compensation, with $3.6 million reported in 2026Q1, which effectively masks the true economic cost of operations and dilutes existing shareholders while the company continues to burn through its remaining $4.95 million in cash.
The persistent use of equity-based incentives during a period of severe cash depletion suggests a misalignment between management compensation and shareholder value creation. This practice warrants further investigation into the long-term impact on share count and the potential for future dilutive financing events.
Quick answers to the most common questions about buying SCLX stock.
Scilex Holding Company (SCLX) generated $3.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Scilex Holding Company (SCLX) generated $3.7M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Scilex Holding Company (SCLX) spent $0.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.